Hemadri Cements Ltd.
Hemadri Cements Ltd. (HEMACEM.BO) Stock Competitors & Peer Comparison
See (HEMACEM.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Construction Materials Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HEMACEM.BO | ₹50.88 | +2.62% | 339.4M | N/A | N/A | N/A |
| ULTRACEMCO.NS | ₹11,573.00 | +0.49% | 3.4T | 41.68 | ₹277.66 | +0.67% |
| ULTRACEMCO.BO | ₹11,571.80 | +0.48% | 3.4T | 41.70 | ₹277.52 | +0.67% |
| GRASIM.BO | ₹2,946.05 | +1.49% | 2T | 46.23 | ₹63.73 | +0.34% |
| GRASIM.NS | ₹2,945.60 | +1.47% | 2T | 44.10 | ₹66.79 | +0.34% |
| AMBUJACEM.BO | ₹438.50 | +2.73% | 1.1T | 29.27 | ₹14.98 | +0.47% |
| AMBUJACEM.NS | ₹438.40 | +2.68% | 1.1T | 23.00 | ₹19.06 | +0.47% |
| SHREECEM.NS | ₹24,995.00 | +0.54% | 901.8B | 51.83 | ₹482.28 | +0.56% |
| SHREECEM.BO | ₹24,994.80 | +0.55% | 901.8B | 52.49 | ₹476.14 | +0.56% |
| JKCEMENT.BO | ₹5,440.00 | +1.35% | 420.3B | 41.27 | ₹131.80 | +0.28% |
Stock Comparison
HEMACEM.BO vs ULTRACEMCO.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, ULTRACEMCO.NS has a market cap of 3.4T. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while ULTRACEMCO.NS trades at ₹11,573.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas ULTRACEMCO.NS's P/E ratio is 41.68. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to ULTRACEMCO.NS's ROE of +0.11%. Regarding short-term risk, HEMACEM.BO is more volatile compared to ULTRACEMCO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check ULTRACEMCO.NS's competition here
HEMACEM.BO vs ULTRACEMCO.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, ULTRACEMCO.BO has a market cap of 3.4T. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while ULTRACEMCO.BO trades at ₹11,571.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas ULTRACEMCO.BO's P/E ratio is 41.70. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to ULTRACEMCO.BO's ROE of +0.11%. Regarding short-term risk, HEMACEM.BO is more volatile compared to ULTRACEMCO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check ULTRACEMCO.BO's competition here
HEMACEM.BO vs GRASIM.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, GRASIM.BO has a market cap of 2T. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while GRASIM.BO trades at ₹2,946.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas GRASIM.BO's P/E ratio is 46.23. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to GRASIM.BO's ROE of +0.03%. Regarding short-term risk, HEMACEM.BO is more volatile compared to GRASIM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check GRASIM.BO's competition here
HEMACEM.BO vs GRASIM.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, GRASIM.NS has a market cap of 2T. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while GRASIM.NS trades at ₹2,945.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas GRASIM.NS's P/E ratio is 44.10. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to GRASIM.NS's ROE of +0.03%. Regarding short-term risk, HEMACEM.BO is more volatile compared to GRASIM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check GRASIM.NS's competition here
HEMACEM.BO vs AMBUJACEM.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, AMBUJACEM.BO has a market cap of 1.1T. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while AMBUJACEM.BO trades at ₹438.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas AMBUJACEM.BO's P/E ratio is 29.27. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to AMBUJACEM.BO's ROE of +0.08%. Regarding short-term risk, HEMACEM.BO is more volatile compared to AMBUJACEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check AMBUJACEM.BO's competition here
HEMACEM.BO vs AMBUJACEM.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, AMBUJACEM.NS has a market cap of 1.1T. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while AMBUJACEM.NS trades at ₹438.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas AMBUJACEM.NS's P/E ratio is 23.00. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to AMBUJACEM.NS's ROE of +0.08%. Regarding short-term risk, HEMACEM.BO is more volatile compared to AMBUJACEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check AMBUJACEM.NS's competition here
HEMACEM.BO vs SHREECEM.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, SHREECEM.NS has a market cap of 901.8B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while SHREECEM.NS trades at ₹24,995.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas SHREECEM.NS's P/E ratio is 51.83. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to SHREECEM.NS's ROE of +0.08%. Regarding short-term risk, HEMACEM.BO is more volatile compared to SHREECEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check SHREECEM.NS's competition here
HEMACEM.BO vs SHREECEM.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, SHREECEM.BO has a market cap of 901.8B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while SHREECEM.BO trades at ₹24,994.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas SHREECEM.BO's P/E ratio is 52.49. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to SHREECEM.BO's ROE of +0.08%. Regarding short-term risk, HEMACEM.BO is more volatile compared to SHREECEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check SHREECEM.BO's competition here
HEMACEM.BO vs JKCEMENT.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, JKCEMENT.BO has a market cap of 420.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while JKCEMENT.BO trades at ₹5,440.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas JKCEMENT.BO's P/E ratio is 41.27. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to JKCEMENT.BO's ROE of +0.17%. Regarding short-term risk, HEMACEM.BO is more volatile compared to JKCEMENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check JKCEMENT.BO's competition here
HEMACEM.BO vs JKCEMENT.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, JKCEMENT.NS has a market cap of 419B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while JKCEMENT.NS trades at ₹5,422.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas JKCEMENT.NS's P/E ratio is 41.07. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to JKCEMENT.NS's ROE of +0.17%. Regarding short-term risk, HEMACEM.BO is more volatile compared to JKCEMENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check JKCEMENT.NS's competition here
HEMACEM.BO vs DALBHARAT.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, DALBHARAT.NS has a market cap of 333.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while DALBHARAT.NS trades at ₹1,776.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas DALBHARAT.NS's P/E ratio is 29.26. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to DALBHARAT.NS's ROE of +0.06%. Regarding short-term risk, HEMACEM.BO is more volatile compared to DALBHARAT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check DALBHARAT.NS's competition here
HEMACEM.BO vs DALBHARAT.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, DALBHARAT.BO has a market cap of 333.2B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while DALBHARAT.BO trades at ₹1,776.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas DALBHARAT.BO's P/E ratio is 29.24. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to DALBHARAT.BO's ROE of +0.06%. Regarding short-term risk, HEMACEM.BO is more volatile compared to DALBHARAT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check DALBHARAT.BO's competition here
HEMACEM.BO vs ACC.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, ACC.NS has a market cap of 256.6B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while ACC.NS trades at ₹1,366.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas ACC.NS's P/E ratio is 12.04. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to ACC.NS's ROE of +0.11%. Regarding short-term risk, HEMACEM.BO is more volatile compared to ACC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check ACC.NS's competition here
HEMACEM.BO vs ACC.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, ACC.BO has a market cap of 256.6B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while ACC.BO trades at ₹1,366.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas ACC.BO's P/E ratio is 9.71. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to ACC.BO's ROE of +0.11%. Regarding short-term risk, HEMACEM.BO is more volatile compared to ACC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check ACC.BO's competition here
HEMACEM.BO vs RAMCOCEM.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, RAMCOCEM.BO has a market cap of 219.8B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while RAMCOCEM.BO trades at ₹930.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas RAMCOCEM.BO's P/E ratio is 38.29. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to RAMCOCEM.BO's ROE of +0.08%. Regarding short-term risk, HEMACEM.BO is more volatile compared to RAMCOCEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check RAMCOCEM.BO's competition here
HEMACEM.BO vs RAMCOCEM.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, RAMCOCEM.NS has a market cap of 219.7B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while RAMCOCEM.NS trades at ₹929.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas RAMCOCEM.NS's P/E ratio is 38.22. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to RAMCOCEM.NS's ROE of +0.08%. Regarding short-term risk, HEMACEM.BO is more volatile compared to RAMCOCEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check RAMCOCEM.NS's competition here
HEMACEM.BO vs JSWCEMENT.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, JSWCEMENT.NS has a market cap of 164.7B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while JSWCEMENT.NS trades at ₹122.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas JSWCEMENT.NS's P/E ratio is -15.03. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to JSWCEMENT.NS's ROE of -0.26%. Regarding short-term risk, HEMACEM.BO is more volatile compared to JSWCEMENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check JSWCEMENT.NS's competition here
HEMACEM.BO vs JSWCEMENT.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, JSWCEMENT.BO has a market cap of 164.7B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while JSWCEMENT.BO trades at ₹122.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas JSWCEMENT.BO's P/E ratio is -15.03. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to JSWCEMENT.BO's ROE of -0.26%. Regarding short-term risk, HEMACEM.BO is more volatile compared to JSWCEMENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check JSWCEMENT.BO's competition here
HEMACEM.BO vs INDIACEM.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, INDIACEM.BO has a market cap of 123.2B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while INDIACEM.BO trades at ₹397.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas INDIACEM.BO's P/E ratio is -184.91. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to INDIACEM.BO's ROE of -0.01%. Regarding short-term risk, HEMACEM.BO is more volatile compared to INDIACEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check INDIACEM.BO's competition here
HEMACEM.BO vs INDIACEM.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, INDIACEM.NS has a market cap of 122.9B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while INDIACEM.NS trades at ₹396.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas INDIACEM.NS's P/E ratio is -182.70. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to INDIACEM.NS's ROE of -0.01%. Regarding short-term risk, HEMACEM.BO is more volatile compared to INDIACEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check INDIACEM.NS's competition here
HEMACEM.BO vs NUVOCO.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, NUVOCO.BO has a market cap of 113.7B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while NUVOCO.BO trades at ₹318.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas NUVOCO.BO's P/E ratio is 31.59. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to NUVOCO.BO's ROE of +0.04%. Regarding short-term risk, HEMACEM.BO is more volatile compared to NUVOCO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check NUVOCO.BO's competition here
HEMACEM.BO vs NUVOCO.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, NUVOCO.NS has a market cap of 113.7B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while NUVOCO.NS trades at ₹318.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas NUVOCO.NS's P/E ratio is 31.65. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to NUVOCO.NS's ROE of +0.04%. Regarding short-term risk, HEMACEM.BO is more volatile compared to NUVOCO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check NUVOCO.NS's competition here
HEMACEM.BO vs STARCEMENT.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, STARCEMENT.NS has a market cap of 87.6B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while STARCEMENT.NS trades at ₹216.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas STARCEMENT.NS's P/E ratio is 23.75. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to STARCEMENT.NS's ROE of +0.13%. Regarding short-term risk, HEMACEM.BO is more volatile compared to STARCEMENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check STARCEMENT.NS's competition here
HEMACEM.BO vs STARCEMENT.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, STARCEMENT.BO has a market cap of 87.5B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while STARCEMENT.BO trades at ₹216.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas STARCEMENT.BO's P/E ratio is 23.72. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to STARCEMENT.BO's ROE of +0.13%. Regarding short-term risk, HEMACEM.BO is more volatile compared to STARCEMENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check STARCEMENT.BO's competition here
HEMACEM.BO vs JKLAKSHMI.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, JKLAKSHMI.BO has a market cap of 82.4B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while JKLAKSHMI.BO trades at ₹664.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas JKLAKSHMI.BO's P/E ratio is 17.77. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to JKLAKSHMI.BO's ROE of +0.13%. Regarding short-term risk, HEMACEM.BO is more volatile compared to JKLAKSHMI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check JKLAKSHMI.BO's competition here
HEMACEM.BO vs JKLAKSHMI.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, JKLAKSHMI.NS has a market cap of 82.4B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while JKLAKSHMI.NS trades at ₹663.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas JKLAKSHMI.NS's P/E ratio is 17.75. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to JKLAKSHMI.NS's ROE of +0.13%. Regarding short-term risk, HEMACEM.BO is more volatile compared to JKLAKSHMI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check JKLAKSHMI.NS's competition here
HEMACEM.BO vs BIRLACORPN.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, BIRLACORPN.BO has a market cap of 79.6B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while BIRLACORPN.BO trades at ₹1,033.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas BIRLACORPN.BO's P/E ratio is 15.32. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to BIRLACORPN.BO's ROE of +0.08%. Regarding short-term risk, HEMACEM.BO is more volatile compared to BIRLACORPN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check BIRLACORPN.BO's competition here
HEMACEM.BO vs BIRLACORPN.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, BIRLACORPN.NS has a market cap of 79.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while BIRLACORPN.NS trades at ₹1,030.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas BIRLACORPN.NS's P/E ratio is 14.23. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to BIRLACORPN.NS's ROE of +0.08%. Regarding short-term risk, HEMACEM.BO is more volatile compared to BIRLACORPN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check BIRLACORPN.NS's competition here
HEMACEM.BO vs PRSMJOHNSN.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, PRSMJOHNSN.BO has a market cap of 63.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while PRSMJOHNSN.BO trades at ₹125.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas PRSMJOHNSN.BO's P/E ratio is 32.31. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to PRSMJOHNSN.BO's ROE of +0.12%. Regarding short-term risk, HEMACEM.BO is more volatile compared to PRSMJOHNSN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check PRSMJOHNSN.BO's competition here
HEMACEM.BO vs PRSMJOHNSN.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, PRSMJOHNSN.NS has a market cap of 63.2B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while PRSMJOHNSN.NS trades at ₹125.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas PRSMJOHNSN.NS's P/E ratio is 32.28. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to PRSMJOHNSN.NS's ROE of +0.12%. Regarding short-term risk, HEMACEM.BO is more volatile compared to PRSMJOHNSN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check PRSMJOHNSN.NS's competition here
HEMACEM.BO vs HEIDELBERG.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, HEIDELBERG.NS has a market cap of 34.8B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while HEIDELBERG.NS trades at ₹153.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas HEIDELBERG.NS's P/E ratio is 24.95. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to HEIDELBERG.NS's ROE of +0.10%. Regarding short-term risk, HEMACEM.BO is more volatile compared to HEIDELBERG.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check HEIDELBERG.NS's competition here
HEMACEM.BO vs HEIDELBERG.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, HEIDELBERG.BO has a market cap of 34.8B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while HEIDELBERG.BO trades at ₹153.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas HEIDELBERG.BO's P/E ratio is 27.05. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to HEIDELBERG.BO's ROE of +0.10%. Regarding short-term risk, HEMACEM.BO is more volatile compared to HEIDELBERG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check HEIDELBERG.BO's competition here
HEMACEM.BO vs ORIENTCEM.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, ORIENTCEM.BO has a market cap of 28.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while ORIENTCEM.BO trades at ₹137.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas ORIENTCEM.BO's P/E ratio is 8.39. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to ORIENTCEM.BO's ROE of +0.17%. Regarding short-term risk, HEMACEM.BO is more volatile compared to ORIENTCEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check ORIENTCEM.BO's competition here
HEMACEM.BO vs ORIENTCEM.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, ORIENTCEM.NS has a market cap of 28.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while ORIENTCEM.NS trades at ₹137.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas ORIENTCEM.NS's P/E ratio is 8.38. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to ORIENTCEM.NS's ROE of +0.17%. Regarding short-term risk, HEMACEM.BO is more volatile compared to ORIENTCEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check ORIENTCEM.NS's competition here
HEMACEM.BO vs MANGLMCEM.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, MANGLMCEM.NS has a market cap of 24.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while MANGLMCEM.NS trades at ₹883.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas MANGLMCEM.NS's P/E ratio is 30.11. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to MANGLMCEM.NS's ROE of +0.09%. Regarding short-term risk, HEMACEM.BO is more volatile compared to MANGLMCEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check MANGLMCEM.NS's competition here
HEMACEM.BO vs MANGLMCEM.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, MANGLMCEM.BO has a market cap of 24.2B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while MANGLMCEM.BO trades at ₹880.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas MANGLMCEM.BO's P/E ratio is 31.39. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to MANGLMCEM.BO's ROE of +0.09%. Regarding short-term risk, HEMACEM.BO is more volatile compared to MANGLMCEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check MANGLMCEM.BO's competition here
HEMACEM.BO vs EPACK.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, EPACK.NS has a market cap of 23.7B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while EPACK.NS trades at ₹246.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas EPACK.NS's P/E ratio is 57.73. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to EPACK.NS's ROE of +0.04%. Regarding short-term risk, HEMACEM.BO is more volatile compared to EPACK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check EPACK.NS's competition here
HEMACEM.BO vs SAGCEM.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, SAGCEM.BO has a market cap of 23.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while SAGCEM.BO trades at ₹178.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas SAGCEM.BO's P/E ratio is -13.93. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to SAGCEM.BO's ROE of -0.10%. Regarding short-term risk, HEMACEM.BO is more volatile compared to SAGCEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check SAGCEM.BO's competition here
HEMACEM.BO vs SAGCEM.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, SAGCEM.NS has a market cap of 23.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while SAGCEM.NS trades at ₹177.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas SAGCEM.NS's P/E ratio is -14.39. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to SAGCEM.NS's ROE of -0.10%. Regarding short-term risk, HEMACEM.BO is more volatile compared to SAGCEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check SAGCEM.NS's competition here
HEMACEM.BO vs KCP.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, KCP.NS has a market cap of 21B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while KCP.NS trades at ₹162.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas KCP.NS's P/E ratio is 14.01. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to KCP.NS's ROE of +0.09%. Regarding short-term risk, HEMACEM.BO is more volatile compared to KCP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check KCP.NS's competition here
HEMACEM.BO vs KCP.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, KCP.BO has a market cap of 20.9B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while KCP.BO trades at ₹162.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas KCP.BO's P/E ratio is 13.97. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to KCP.BO's ROE of +0.09%. Regarding short-term risk, HEMACEM.BO is more volatile compared to KCP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check KCP.BO's competition here
HEMACEM.BO vs UDAICEMENT.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, UDAICEMENT.NS has a market cap of 20.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while UDAICEMENT.NS trades at ₹36.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas UDAICEMENT.NS's P/E ratio is 201.28. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to UDAICEMENT.NS's ROE of +0.06%. Regarding short-term risk, HEMACEM.BO is more volatile compared to UDAICEMENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check UDAICEMENT.NS's competition here
HEMACEM.BO vs UDAICEMENT.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, UDAICEMENT.BO has a market cap of 20.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while UDAICEMENT.BO trades at ₹36.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas UDAICEMENT.BO's P/E ratio is 201.06. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to UDAICEMENT.BO's ROE of +0.06%. Regarding short-term risk, HEMACEM.BO is more volatile compared to UDAICEMENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check UDAICEMENT.BO's competition here
HEMACEM.BO vs SANGHIIND.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, SANGHIIND.BO has a market cap of 13B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while SANGHIIND.BO trades at ₹50.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas SANGHIIND.BO's P/E ratio is -3.05. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to SANGHIIND.BO's ROE of -0.69%. Regarding short-term risk, HEMACEM.BO is more volatile compared to SANGHIIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check SANGHIIND.BO's competition here
HEMACEM.BO vs SANGHIIND.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, SANGHIIND.NS has a market cap of 12.9B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while SANGHIIND.NS trades at ₹49.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas SANGHIIND.NS's P/E ratio is -3.04. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to SANGHIIND.NS's ROE of -0.69%. Regarding short-term risk, HEMACEM.BO is more volatile compared to SANGHIIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check SANGHIIND.NS's competition here
HEMACEM.BO vs IFGLEXPOR.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, IFGLEXPOR.BO has a market cap of 12.4B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while IFGLEXPOR.BO trades at ₹172.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas IFGLEXPOR.BO's P/E ratio is 43.05. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to IFGLEXPOR.BO's ROE of +0.03%. Regarding short-term risk, HEMACEM.BO is more volatile compared to IFGLEXPOR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check IFGLEXPOR.BO's competition here
HEMACEM.BO vs IFGLEXPOR.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, IFGLEXPOR.NS has a market cap of 12.4B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while IFGLEXPOR.NS trades at ₹172.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas IFGLEXPOR.NS's P/E ratio is 43.12. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to IFGLEXPOR.NS's ROE of +0.03%. Regarding short-term risk, HEMACEM.BO is more volatile compared to IFGLEXPOR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check IFGLEXPOR.NS's competition here
HEMACEM.BO vs SHREDIGCEM.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, SHREDIGCEM.BO has a market cap of 10.8B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while SHREDIGCEM.BO trades at ₹73.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas SHREDIGCEM.BO's P/E ratio is 43.22. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to SHREDIGCEM.BO's ROE of +0.07%. Regarding short-term risk, HEMACEM.BO is more volatile compared to SHREDIGCEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check SHREDIGCEM.BO's competition here
HEMACEM.BO vs SHREDIGCEM.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, SHREDIGCEM.NS has a market cap of 10.7B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while SHREDIGCEM.NS trades at ₹72.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas SHREDIGCEM.NS's P/E ratio is 42.99. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to SHREDIGCEM.NS's ROE of +0.07%. Regarding short-term risk, HEMACEM.BO is more volatile compared to SHREDIGCEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check SHREDIGCEM.NS's competition here
HEMACEM.BO vs ORIRAIL.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, ORIRAIL.BO has a market cap of 10.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while ORIRAIL.BO trades at ₹153.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas ORIRAIL.BO's P/E ratio is 27.84. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to ORIRAIL.BO's ROE of +0.10%. Regarding short-term risk, HEMACEM.BO is more volatile compared to ORIRAIL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check ORIRAIL.BO's competition here
HEMACEM.BO vs DECCANCE.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, DECCANCE.NS has a market cap of 9.1B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while DECCANCE.NS trades at ₹646.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas DECCANCE.NS's P/E ratio is 28.50. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to DECCANCE.NS's ROE of +0.04%. Regarding short-term risk, HEMACEM.BO is less volatile compared to DECCANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HEMACEM.BO.Check DECCANCE.NS's competition here
HEMACEM.BO vs DECCANCE.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, DECCANCE.BO has a market cap of 9B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while DECCANCE.BO trades at ₹642.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas DECCANCE.BO's P/E ratio is 27.12. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to DECCANCE.BO's ROE of +0.04%. Regarding short-term risk, HEMACEM.BO is less volatile compared to DECCANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HEMACEM.BO.Check DECCANCE.BO's competition here
HEMACEM.BO vs APOLLOPIPES.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, APOLLOPIPES.BO has a market cap of 9B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while APOLLOPIPES.BO trades at ₹686.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas APOLLOPIPES.BO's P/E ratio is 46.89. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to APOLLOPIPES.BO's ROE of +0.08%. Regarding short-term risk, HEMACEM.BO is more volatile compared to APOLLOPIPES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check APOLLOPIPES.BO's competition here
HEMACEM.BO vs NCLIND.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, NCLIND.NS has a market cap of 7.7B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while NCLIND.NS trades at ₹170.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas NCLIND.NS's P/E ratio is 12.79. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to NCLIND.NS's ROE of +0.07%. Regarding short-term risk, HEMACEM.BO is more volatile compared to NCLIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check NCLIND.NS's competition here
HEMACEM.BO vs NCLIND.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, NCLIND.BO has a market cap of 7.7B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while NCLIND.BO trades at ₹170.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas NCLIND.BO's P/E ratio is 15.55. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to NCLIND.BO's ROE of +0.07%. Regarding short-term risk, HEMACEM.BO is more volatile compared to NCLIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check NCLIND.BO's competition here
HEMACEM.BO vs SAURASHCEM.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, SAURASHCEM.NS has a market cap of 6.9B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while SAURASHCEM.NS trades at ₹61.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas SAURASHCEM.NS's P/E ratio is 24.08. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to SAURASHCEM.NS's ROE of +0.03%. Regarding short-term risk, HEMACEM.BO is more volatile compared to SAURASHCEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check SAURASHCEM.NS's competition here
HEMACEM.BO vs SAURASHCEM.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, SAURASHCEM.BO has a market cap of 6.9B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while SAURASHCEM.BO trades at ₹61.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas SAURASHCEM.BO's P/E ratio is 24.07. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to SAURASHCEM.BO's ROE of +0.03%. Regarding short-term risk, HEMACEM.BO is more volatile compared to SAURASHCEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check SAURASHCEM.BO's competition here
HEMACEM.BO vs ACL.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, ACL.NS has a market cap of 5.4B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while ACL.NS trades at ₹57.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas ACL.NS's P/E ratio is -3.27. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to ACL.NS's ROE of -1.06%. Regarding short-term risk, HEMACEM.BO is less volatile compared to ACL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HEMACEM.BO.Check ACL.NS's competition here
HEMACEM.BO vs SHIVACEM.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, SHIVACEM.BO has a market cap of 5.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while SHIVACEM.BO trades at ₹18.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas SHIVACEM.BO's P/E ratio is -3.61. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to SHIVACEM.BO's ROE of -2.23%. Regarding short-term risk, HEMACEM.BO is more volatile compared to SHIVACEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check SHIVACEM.BO's competition here
HEMACEM.BO vs ACL.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, ACL.BO has a market cap of 5.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while ACL.BO trades at ₹57.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas ACL.BO's P/E ratio is -3.20. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to ACL.BO's ROE of -1.06%. Regarding short-term risk, HEMACEM.BO is more volatile compared to ACL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check ACL.BO's competition here
HEMACEM.BO vs ZODIAC.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, ZODIAC.BO has a market cap of 4.5B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while ZODIAC.BO trades at ₹298.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas ZODIAC.BO's P/E ratio is -70.89. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to ZODIAC.BO's ROE of +0.21%. Regarding short-term risk, HEMACEM.BO is more volatile compared to ZODIAC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check ZODIAC.BO's competition here
HEMACEM.BO vs ZODIAC.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, ZODIAC.NS has a market cap of 4.5B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while ZODIAC.NS trades at ₹294.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas ZODIAC.NS's P/E ratio is 78.97. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to ZODIAC.NS's ROE of +0.21%. Regarding short-term risk, HEMACEM.BO is more volatile compared to ZODIAC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check ZODIAC.NS's competition here
HEMACEM.BO vs KESORAMIND.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, KESORAMIND.BO has a market cap of 4.2B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while KESORAMIND.BO trades at ₹13.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas KESORAMIND.BO's P/E ratio is -2.99. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to KESORAMIND.BO's ROE of +18.55%. Regarding short-term risk, HEMACEM.BO is more volatile compared to KESORAMIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check KESORAMIND.BO's competition here
HEMACEM.BO vs KESORAMIND.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, KESORAMIND.NS has a market cap of 4.2B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while KESORAMIND.NS trades at ₹13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas KESORAMIND.NS's P/E ratio is -2.86. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to KESORAMIND.NS's ROE of +18.55%. Regarding short-term risk, HEMACEM.BO is more volatile compared to KESORAMIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check KESORAMIND.NS's competition here
HEMACEM.BO vs VISHNUINFR.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, VISHNUINFR.NS has a market cap of 3.8B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while VISHNUINFR.NS trades at ₹153.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas VISHNUINFR.NS's P/E ratio is 12.88. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to VISHNUINFR.NS's ROE of N/A. Regarding short-term risk, HEMACEM.BO is more volatile compared to VISHNUINFR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check VISHNUINFR.NS's competition here
HEMACEM.BO vs SAHYADRI.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, SAHYADRI.NS has a market cap of 3.5B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while SAHYADRI.NS trades at ₹320.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas SAHYADRI.NS's P/E ratio is 15.42. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to SAHYADRI.NS's ROE of +0.06%. Regarding short-term risk, HEMACEM.BO is less volatile compared to SAHYADRI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HEMACEM.BO.Check SAHYADRI.NS's competition here
HEMACEM.BO vs APCL.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, APCL.BO has a market cap of 3.4B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while APCL.BO trades at ₹115.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas APCL.BO's P/E ratio is -8.27. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to APCL.BO's ROE of -0.18%. Regarding short-term risk, HEMACEM.BO is more volatile compared to APCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check APCL.BO's competition here
HEMACEM.BO vs APCL.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, APCL.NS has a market cap of 3.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while APCL.NS trades at ₹113.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas APCL.NS's P/E ratio is -8.12. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to APCL.NS's ROE of -0.18%. Regarding short-term risk, HEMACEM.BO is more volatile compared to APCL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check APCL.NS's competition here
HEMACEM.BO vs NAVKAR.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, NAVKAR.BO has a market cap of 3.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while NAVKAR.BO trades at ₹14.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas NAVKAR.BO's P/E ratio is 145.10. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to NAVKAR.BO's ROE of -0.01%. Regarding short-term risk, HEMACEM.BO is less volatile compared to NAVKAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HEMACEM.BO.Check NAVKAR.BO's competition here
HEMACEM.BO vs GSCLCEMENT.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, GSCLCEMENT.NS has a market cap of 3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while GSCLCEMENT.NS trades at ₹33.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas GSCLCEMENT.NS's P/E ratio is -87.37. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to GSCLCEMENT.NS's ROE of +0.04%. Regarding short-term risk, HEMACEM.BO is more volatile compared to GSCLCEMENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check GSCLCEMENT.NS's competition here
HEMACEM.BO vs SKCIL.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, SKCIL.BO has a market cap of 2.9B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while SKCIL.BO trades at ₹164.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas SKCIL.BO's P/E ratio is -253.77. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to SKCIL.BO's ROE of -0.01%. Regarding short-term risk, HEMACEM.BO is more volatile compared to SKCIL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check SKCIL.BO's competition here
HEMACEM.BO vs GSLSU.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, GSLSU.BO has a market cap of 2.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while GSLSU.BO trades at ₹55.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas GSLSU.BO's P/E ratio is -12.62. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to GSLSU.BO's ROE of -0.06%. Regarding short-term risk, HEMACEM.BO is more volatile compared to GSLSU.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check GSLSU.BO's competition here
HEMACEM.BO vs GSLSU.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, GSLSU.NS has a market cap of 2.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while GSLSU.NS trades at ₹53.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas GSLSU.NS's P/E ratio is -12.29. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to GSLSU.NS's ROE of -0.06%. Regarding short-term risk, HEMACEM.BO is more volatile compared to GSLSU.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check GSLSU.NS's competition here
HEMACEM.BO vs ASIIL.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, ASIIL.BO has a market cap of 2.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while ASIIL.BO trades at ₹25.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas ASIIL.BO's P/E ratio is 8.65. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to ASIIL.BO's ROE of +0.08%. Regarding short-term risk, HEMACEM.BO is more volatile compared to ASIIL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check ASIIL.BO's competition here
HEMACEM.BO vs BRPL.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, BRPL.BO has a market cap of 1.6B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while BRPL.BO trades at ₹116.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas BRPL.BO's P/E ratio is 17.43. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to BRPL.BO's ROE of +0.27%. Regarding short-term risk, HEMACEM.BO is more volatile compared to BRPL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check BRPL.BO's competition here
HEMACEM.BO vs KEIL.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, KEIL.BO has a market cap of 1.4B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while KEIL.BO trades at ₹16.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas KEIL.BO's P/E ratio is -1616.00. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to KEIL.BO's ROE of -0.00%. Regarding short-term risk, HEMACEM.BO is less volatile compared to KEIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HEMACEM.BO.Check KEIL.BO's competition here
HEMACEM.BO vs TRL.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, TRL.BO has a market cap of 1.3B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while TRL.BO trades at ₹102.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas TRL.BO's P/E ratio is 30.46. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to TRL.BO's ROE of +0.06%. Regarding short-term risk, HEMACEM.BO is more volatile compared to TRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check TRL.BO's competition here
HEMACEM.BO vs GLITTEKG.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, GLITTEKG.BO has a market cap of 1.2B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while GLITTEKG.BO trades at ₹46.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas GLITTEKG.BO's P/E ratio is 4.75. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to GLITTEKG.BO's ROE of +4.29%. Regarding short-term risk, HEMACEM.BO is less volatile compared to GLITTEKG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HEMACEM.BO.Check GLITTEKG.BO's competition here
HEMACEM.BO vs ALUWIND.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, ALUWIND.NS has a market cap of 1.2B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while ALUWIND.NS trades at ₹48.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas ALUWIND.NS's P/E ratio is 11.02. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to ALUWIND.NS's ROE of N/A. Regarding short-term risk, HEMACEM.BO is less volatile compared to ALUWIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HEMACEM.BO.Check ALUWIND.NS's competition here
HEMACEM.BO vs RISHILASE.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, RISHILASE.BO has a market cap of 1.1B. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while RISHILASE.BO trades at ₹122.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas RISHILASE.BO's P/E ratio is 14.20. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to RISHILASE.BO's ROE of +0.10%. Regarding short-term risk, HEMACEM.BO is more volatile compared to RISHILASE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check RISHILASE.BO's competition here
HEMACEM.BO vs KAKATCEM.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, KAKATCEM.BO has a market cap of 987.3M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while KAKATCEM.BO trades at ₹127.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas KAKATCEM.BO's P/E ratio is -3.63. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to KAKATCEM.BO's ROE of -0.13%. Regarding short-term risk, HEMACEM.BO is more volatile compared to KAKATCEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check KAKATCEM.BO's competition here
HEMACEM.BO vs PACIFICI.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, PACIFICI.BO has a market cap of 978.1M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while PACIFICI.BO trades at ₹141.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas PACIFICI.BO's P/E ratio is 24.85. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to PACIFICI.BO's ROE of +0.01%. Regarding short-term risk, HEMACEM.BO is more volatile compared to PACIFICI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check PACIFICI.BO's competition here
HEMACEM.BO vs KAKATCEM.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, KAKATCEM.NS has a market cap of 976.7M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while KAKATCEM.NS trades at ₹125.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas KAKATCEM.NS's P/E ratio is -3.55. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to KAKATCEM.NS's ROE of -0.13%. Regarding short-term risk, HEMACEM.BO is more volatile compared to KAKATCEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check KAKATCEM.NS's competition here
HEMACEM.BO vs PANCM.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, PANCM.BO has a market cap of 954.5M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while PANCM.BO trades at ₹119.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas PANCM.BO's P/E ratio is -1.09. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to PANCM.BO's ROE of +0.38%. Regarding short-term risk, HEMACEM.BO is more volatile compared to PANCM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check PANCM.BO's competition here
HEMACEM.BO vs BVCL.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, BVCL.NS has a market cap of 952M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while BVCL.NS trades at ₹42.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas BVCL.NS's P/E ratio is 4296.00. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to BVCL.NS's ROE of +0.00%. Regarding short-term risk, HEMACEM.BO is less volatile compared to BVCL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HEMACEM.BO.Check BVCL.NS's competition here
HEMACEM.BO vs BVCL.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, BVCL.BO has a market cap of 935.4M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while BVCL.BO trades at ₹42.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas BVCL.BO's P/E ratio is 4221.00. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to BVCL.BO's ROE of +0.00%. Regarding short-term risk, HEMACEM.BO is more volatile compared to BVCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check BVCL.BO's competition here
HEMACEM.BO vs NAVKARURB.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, NAVKARURB.NS has a market cap of 897.7M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while NAVKARURB.NS trades at ₹0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas NAVKARURB.NS's P/E ratio is -11.43. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to NAVKARURB.NS's ROE of +0.00%. Regarding short-term risk, HEMACEM.BO is more volatile compared to NAVKARURB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check NAVKARURB.NS's competition here
HEMACEM.BO vs NAVKARURB.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, NAVKARURB.BO has a market cap of 886.5M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while NAVKARURB.BO trades at ₹0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas NAVKARURB.BO's P/E ratio is -11.29. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to NAVKARURB.BO's ROE of +0.00%. Regarding short-term risk, HEMACEM.BO is more volatile compared to NAVKARURB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check NAVKARURB.BO's competition here
HEMACEM.BO vs NILACHAL.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, NILACHAL.BO has a market cap of 863.5M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while NILACHAL.BO trades at ₹42.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas NILACHAL.BO's P/E ratio is -17.82. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to NILACHAL.BO's ROE of +0.17%. Regarding short-term risk, HEMACEM.BO is more volatile compared to NILACHAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check NILACHAL.BO's competition here
HEMACEM.BO vs REFRACTORY.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, REFRACTORY.NS has a market cap of 836M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while REFRACTORY.NS trades at ₹38.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas REFRACTORY.NS's P/E ratio is 13.79. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to REFRACTORY.NS's ROE of N/A. Regarding short-term risk, HEMACEM.BO is more volatile compared to REFRACTORY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check REFRACTORY.NS's competition here
HEMACEM.BO vs ELEMARB.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, ELEMARB.BO has a market cap of 749.8M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while ELEMARB.BO trades at ₹204.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas ELEMARB.BO's P/E ratio is 17.06. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to ELEMARB.BO's ROE of +0.02%. Regarding short-term risk, HEMACEM.BO is less volatile compared to ELEMARB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HEMACEM.BO.Check ELEMARB.BO's competition here
HEMACEM.BO vs RESTILE.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, RESTILE.BO has a market cap of 733.2M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while RESTILE.BO trades at ₹7.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas RESTILE.BO's P/E ratio is -106.57. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to RESTILE.BO's ROE of +0.00%. Regarding short-term risk, HEMACEM.BO is more volatile compared to RESTILE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check RESTILE.BO's competition here
HEMACEM.BO vs AHMDSTE.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, AHMDSTE.BO has a market cap of 651.4M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while AHMDSTE.BO trades at ₹159.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas AHMDSTE.BO's P/E ratio is 13.28. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to AHMDSTE.BO's ROE of +0.22%. Regarding short-term risk, HEMACEM.BO is less volatile compared to AHMDSTE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HEMACEM.BO.Check AHMDSTE.BO's competition here
HEMACEM.BO vs CEETAIN.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, CEETAIN.BO has a market cap of 644.5M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while CEETAIN.BO trades at ₹44.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas CEETAIN.BO's P/E ratio is 177.76. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to CEETAIN.BO's ROE of +0.01%. Regarding short-term risk, HEMACEM.BO is less volatile compared to CEETAIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HEMACEM.BO.Check CEETAIN.BO's competition here
HEMACEM.BO vs BURNPUR.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, BURNPUR.NS has a market cap of 568.4M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while BURNPUR.NS trades at ₹33.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas BURNPUR.NS's P/E ratio is -0.21. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to BURNPUR.NS's ROE of +0.10%. Regarding short-term risk, HEMACEM.BO is less volatile compared to BURNPUR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HEMACEM.BO.Check BURNPUR.NS's competition here
HEMACEM.BO vs EFORCE.NS Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, EFORCE.NS has a market cap of 566.3M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while EFORCE.NS trades at ₹24.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas EFORCE.NS's P/E ratio is 44.00. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to EFORCE.NS's ROE of N/A. Regarding short-term risk, HEMACEM.BO is more volatile compared to EFORCE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check EFORCE.NS's competition here
HEMACEM.BO vs SRIKPRIND.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, SRIKPRIND.BO has a market cap of 530.8M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while SRIKPRIND.BO trades at ₹26.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas SRIKPRIND.BO's P/E ratio is 5.16. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to SRIKPRIND.BO's ROE of +0.05%. Regarding short-term risk, HEMACEM.BO is less volatile compared to SRIKPRIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HEMACEM.BO.Check SRIKPRIND.BO's competition here
HEMACEM.BO vs DIVSHKT.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, DIVSHKT.BO has a market cap of 528.5M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while DIVSHKT.BO trades at ₹51.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas DIVSHKT.BO's P/E ratio is 36.50. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to DIVSHKT.BO's ROE of +0.01%. Regarding short-term risk, HEMACEM.BO is more volatile compared to DIVSHKT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HEMACEM.BO.Check DIVSHKT.BO's competition here
HEMACEM.BO vs BHEEMACEM.BO Comparison May 2026
HEMACEM.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HEMACEM.BO stands at 339.4M. In comparison, BHEEMACEM.BO has a market cap of 526.7M. Regarding current trading prices, HEMACEM.BO is priced at ₹50.88, while BHEEMACEM.BO trades at ₹16.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HEMACEM.BO currently has a P/E ratio of N/A, whereas BHEEMACEM.BO's P/E ratio is -1.56. In terms of profitability, HEMACEM.BO's ROE is N/A, compared to BHEEMACEM.BO's ROE of -5.24%. Regarding short-term risk, HEMACEM.BO is less volatile compared to BHEEMACEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HEMACEM.BO.Check BHEEMACEM.BO's competition here